Lenalidomide induced stroke in multiple myeloma

Lenalidomide (Revlimid) is a novel agent used in treatment of multiple myeloma (MM) with an adverse effect of thromboembolic episodes, more commonly, deep vein thrombosis and pulmonary embolism [1]. Venous thromboembolism has emerged as one of the leading complications of the life saving drug [2]. In addition, there is an increased burden of Lenalidomide induced stroke and myocardial infarction [3,4]. Recently, the antiangiogenic agents, in general, and Lenalidomide in particular have been associated with stroke [5, 6]. Furthermore, it was hypothesized that Lenalidomide, a Thalidomide analog, induces less neurotoxicity compared to thalidomide [7, 8].